ARS Pharmaceuticals (SPRY) Accounts Payables (2020 - 2026)

ARS Pharmaceuticals has disclosed Accounts Payables across 7 years of filings, most recently posting $5.8 million for Q1 2026.

• Accounts Payables for Q1 2026 came in at $5.8 million, down 78.37% year-over-year; the trailing twelve-month figure through Mar 2026 was $5.8 million (down 78.37% YoY), and the FY2025 annual result was $5.7 million, down 42.0% from the prior year.
• Accounts Payables came in at $5.8 million for Q1 2026 at ARS Pharmaceuticals, up from $5.7 million in the prior quarter.
• In the past five years, Accounts Payables ranged from a high of $44.3 million in Q2 2025 to a low of $126000.0 in Q3 2022.
• The 5-year median for Accounts Payables is $5.8 million (2026), against an average of $9.6 million.
• Across the five-year window, Accounts Payables plunged 92.67% in 2022 and soared 8586.51% in 2023, its largest moves.
• ARS Pharmaceuticals' Accounts Payables stood at $4.9 million in 2022, then slumped by 56.32% to $2.2 million in 2023, then jumped by 358.22% to $9.9 million in 2024, then slumped by 42.0% to $5.7 million in 2025, then climbed by 2.06% to $5.8 million in 2026.
• The last three Accounts Payables figures came in at $5.8 million (Q1 2026), $5.7 million (Q4 2025), and $1.7 million (Q3 2025), per Business Quant data.